El Shafie, Rami

[["dc.bibliographiccitation.firstpage","641"],["dc.bibliographiccitation.journal","Frontiers in Oncology"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Böhm, Karina"],["dc.contributor.author","Weber, Dorothea"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","Schlaich, Fabian"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Paul, Angela"],["dc.contributor.author","Haefner, Matthias F."],["dc.contributor.author","Katayama, Sonja"],["dc.contributor.author","Hörner-Rieber, Juliane"],["dc.contributor.author","Hoegen, Philipp"],["dc.contributor.author","Löw, Sarah"],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Bernhardt, Denise"],["dc.date.accessioned","2020-07-16T10:33:04Z"],["dc.date.available","2020-07-16T10:33:04Z"],["dc.date.issued","2018"],["dc.description.abstract","Introduction: The purpose of this article is to report our institution's 10-year experience on palliative radiotherapy for the treatment of leptomeningeal carcinomatosis (LC), assessing survival, neurologic outcome, and prognostic factors. Patients and methods: We retrospectively analyzed 110 patients who received palliative radiotherapy for LC between 2008 and 2018. The most common histologies were breast cancer (n = 43, 39.1%) and non-small cell lung cancer (NSCLC) (n = 31, 28.2%). Radiotherapy was administered as whole-brain radiotherapy (WBRT) (n = 51, 46.4%), focal spinal RT (n = 11, 10.0%) or both (n = 47, 42.7%). Twenty-five patients (22.7%) were selected for craniospinal irradiation. Clinical performance and neurologic function were quantified on the neurologic function scale (NFS) before and in response to therapy. A Cox Proportional Hazards model with univariate and multivariate analysis was fitted for survival. Results: Ninety-eight patients (89.1%) died and 12 (10.9%) were alive at the time of analysis. Median OS from LC diagnosis and from the beginning of RT was 13.9 weeks (IQR: 7.1-34.0) and 9.9 weeks (IQR: 5.3-26.3), respectively. In univariate analysis, prognostic of longer OS were a Karnofsky performance scale index (KPI) of ≥70% (HR 0.20, 95%-CI: [0.13; 0.32], p < 0.001), initially moderate neurological deficits (NFS ≤2) (HR 0.32, 95% CI: [0.19; 0.52], p < 0.001), symptom response to RT (HR 0.41, 95%-CI: [0.26; 0.67], p < 0.001) and the administration of systemic therapy (HR 0.51, 95%-CI: [0.33; 0.78], p = 0.002). Prognostic of inferior OS were high-grade myelosuppression (HR 1.78, 95% CI: [1.06; 3.00], p = 0.03) and serum LDH levels >500 U/l (HR 3.62, 95% CI: [1.76; 7.44], p < 0.001). Clinical performance, symptom response and serum LDH stayed independently prognostic for survival in multivariate analysis. RT was well-tolerated and except for grade III myelosuppression in 19 cases (17.3%), no high-grade acute toxicities were observed. Neurologic symptom stabilization was achieved in 83 cases (75.5%) and a sizeable improvement in 39 cases (35.5%). Conclusion: Radiotherapy is a well-tolerated and efficacious means of providing symptom palliation for patients with LC, delaying neurologic deterioration while probably not directly influencing survival. Prognostic factors such as clinical performance, neurologic response and serum LDH can be used for patient stratification to facilitate treatment decisions."],["dc.identifier.doi","10.3389/fonc.2018.00641"],["dc.identifier.pmid","30671384"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67172"],["dc.language.iso","en"],["dc.relation.issn","2234-943X"],["dc.title","Palliative Radiotherapy for Leptomeningeal Carcinomatosis-Analysis of Outcome, Prognostic Factors, and Symptom Response"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","760024"],["dc.bibliographiccitation.journal","Frontiers in Psychology"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Sauer, Christina"],["dc.contributor.author","Lambert, Lena"],["dc.contributor.author","Regnery, Sebastian"],["dc.contributor.author","Windisch, Paul"],["dc.contributor.author","Zaoui, Karim"],["dc.contributor.author","Freudlsperger, Christian"],["dc.contributor.author","Moratin, Julius"],["dc.contributor.author","Farnia, Benjamin"],["dc.contributor.author","Nikendei, Christoph"],["dc.contributor.author","Krauss, Juergen"],["dc.contributor.author","Ehrenthal, Johannes C."],["dc.contributor.author","El Shafie, Rami"],["dc.contributor.author","Hörner-Rieber, Juliane"],["dc.contributor.author","König, Laila"],["dc.contributor.author","Akbaba, Sati"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","Held, Thomas"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Debus, Juergen"],["dc.contributor.author","Friederich, Hans-Christoph"],["dc.contributor.author","Maatouk, Imad"],["dc.date.accessioned","2022-11-17T11:12:55Z"],["dc.date.available","2022-11-17T11:12:55Z"],["dc.date.issued","2021"],["dc.description.abstract","This single-center, single-arm trial investigates the feasibility of a psycho-oncological care program, which aims to reduce psychological distress and improve compliance with radiotherapy with mask fixation in patients with head and neck cancer or brain malignancies. The care program comprised (1) a screening/needs assessment and (2) the provision of a psycho-oncological intervention using imaginative stabilization techniques for distressed patients (distress due to anxiety ≥5) or in a case of subjective interest in the psycho-oncological intervention. Another allocation path to the intervention was directly through the radiation oncologist in charge who classified the patient as: in need of support to tolerate the immobilization device. Of a total of 1,020 screened patients, 257 (25.2%) patients indicated a distress ≥5 and 141 (13.8%) patients reported panic attacks. 25% of the patients reported a subjective interest in psycho-oncological support. A total of 35 patients received the psycho-oncological intervention, of which 74% were assigned by radiation oncologists. In this small patient cohort, no significant pre-post effects in terms of depression, anxiety, distress, and quality of life (mental and physical component scores) could be detected. Our results indicate a good feasibility (interdisciplinary workflow and cooperation, allocation by physicians in charge) of the psycho-oncological care program for this cohort of patients before radiotherapy with mask fixation. The screening results underline the high psychological distress and demand for psycho-oncological support. However, since the utilization of our intervention was low, future studies should reduce the barriers and improve compliance to psycho-oncological services by these patients.Clinical Trial Registration: https://www.drks.de/drks_web/setLocale_EN.do #DRKS00013493."],["dc.identifier.doi","10.3389/fpsyg.2021.760024"],["dc.identifier.pmid","34975651"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/117119"],["dc.language.iso","en"],["dc.relation.issn","1664-1078"],["dc.title","Screening and Psycho-Oncological Support for Patients With Head and Neck Cancer and Brain Malignancies Before Radiotherapy With Mask Fixation: Results of a Feasibility Study"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1916"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","14"],["dc.contributor.affiliation","Küchler, Maike; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","El Shafie, Rami A.; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Adeberg, Sebastian; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Herfarth, Klaus; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","König, Laila; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Lang, Kristin; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Hörner-Rieber, Juliane; 4Heidelberg Institute of Radiation Oncology (HIRO), INF 400, 69120 Heidelberg, Germany; juliane.hoerner-rieber@med.uni-heidelberg.de"],["dc.contributor.affiliation","Plinkert, Peter Karl; 9Department of Otolaryngology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; peter.plinkert@med.uni-heidelberg.de"],["dc.contributor.affiliation","Wick, Wolfgang; 8Department of Neurology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; wolfgang.wick@med.uni-heidelberg.de"],["dc.contributor.affiliation","Sahm, Felix; 3Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Heidelberg, INF 280, 69120 Heidelberg, Germany; felix.sahm@med.uni-heidelberg.de"],["dc.contributor.affiliation","Sprengel, Simon David; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Debus, Jürgen; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.affiliation","Bernhardt, Denise; 1Department of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany; maikekuechler@gmail.de (M.K.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); sebastian.adeberg@med.uni-heidelberg.de (S.A.); klaus.herfarth@med.uni-heidelberg.de (K.H.); laila.koenig@med.uni-heidelberg.de (L.K.); kristin.lang@med.uni-heidelberg.de (K.L.); simon.sprengel@med.uni-heidelberg.de (S.D.S.); juergen.debus@med.uni-heidelberg.de (J.D.)"],["dc.contributor.author","Küchler, Maike"],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Herfarth, Klaus"],["dc.contributor.author","König, Laila"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","Hörner-Rieber, Juliane"],["dc.contributor.author","Plinkert, Peter Karl"],["dc.contributor.author","Wick, Wolfgang"],["dc.contributor.author","Sahm, Felix"],["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","Sprengel, Simon David"],["dc.contributor.author","Debus, Jürgen"],["dc.date.accessioned","2022-05-02T08:09:33Z"],["dc.date.available","2022-05-02T08:09:33Z"],["dc.date.issued","2022"],["dc.date.updated","2022-05-05T11:24:31Z"],["dc.description.abstract","Background: To evaluate differences in local tumor control (LC), symptoms and quality of life (QOL) of 261 patients with VS after stereotactic radiosurgery/hypofractionated stereotactic radiotherapy (SRS/HFSRT) vs. fractionated radiotherapy (FRT) vs. fractionated proton therapy (FPT) were studied. Methods: For SRS/HFSRT (n = 149), the median fraction dose applied was 12 Gy. For FRT (n = 87) and FPT (n = 25), the median cumulative doses applied were 57.6 Gy and 54 Gy (RBE), respectively. FRT and FPT used single median doses of 1.8 Gy/Gy (RBE). Median follow-up was 38 months. We investigated dosimetry for organs at risk and analyzed toxicity and QOL by sending out a questionnaire. Results: LC was 99.5% at 12 months after RT with no statistical difference between treatment groups (p = 0.19). LC was significantly lower in NF2 patients (p = 0.004) and in patients with higher tumor extension grade (p = 0.039). The hearing preservation rate was 97% at 12 months after RT with no statistical difference between treatment groups (p = 0.31). Facial and trigeminal nerve affection after RT occurred as mild symptoms with highest toxicity rate in FPT patients. Conclusion: SRS/HFSRT, FRT and FPT for VS show similar overall clinical and functional outcomes. Cranial nerve impairment rates vary, potentially due to selection bias with larger VS in the FRT and FPT group."],["dc.description.abstract","Background: To evaluate differences in local tumor control (LC), symptoms and quality of life (QOL) of 261 patients with VS after stereotactic radiosurgery/hypofractionated stereotactic radiotherapy (SRS/HFSRT) vs. fractionated radiotherapy (FRT) vs. fractionated proton therapy (FPT) were studied. Methods: For SRS/HFSRT (n = 149), the median fraction dose applied was 12 Gy. For FRT (n = 87) and FPT (n = 25), the median cumulative doses applied were 57.6 Gy and 54 Gy (RBE), respectively. FRT and FPT used single median doses of 1.8 Gy/Gy (RBE). Median follow-up was 38 months. We investigated dosimetry for organs at risk and analyzed toxicity and QOL by sending out a questionnaire. Results: LC was 99.5% at 12 months after RT with no statistical difference between treatment groups (p = 0.19). LC was significantly lower in NF2 patients (p = 0.004) and in patients with higher tumor extension grade (p = 0.039). The hearing preservation rate was 97% at 12 months after RT with no statistical difference between treatment groups (p = 0.31). Facial and trigeminal nerve affection after RT occurred as mild symptoms with highest toxicity rate in FPT patients. Conclusion: SRS/HFSRT, FRT and FPT for VS show similar overall clinical and functional outcomes. Cranial nerve impairment rates vary, potentially due to selection bias with larger VS in the FRT and FPT group."],["dc.identifier.doi","10.3390/cancers14081916"],["dc.identifier.pii","cancers14081916"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/107409"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-561"],["dc.relation.eissn","2072-6694"],["dc.title","Outcome after Radiotherapy for Vestibular Schwannomas (VS)—Differences in Tumor Control, Symptoms and Quality of Life after Radiotherapy with Photon versus Proton Therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","127"],["dc.bibliographiccitation.journal","Cancer Management and Research"],["dc.bibliographiccitation.lastpage","136"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Akbaba, Sati"],["dc.contributor.author","Koschny, Ronald"],["dc.contributor.author","Bougatf, Nina"],["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","Welte, Stefan E."],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Häfner, Matthias"],["dc.contributor.author","Kargus, Steffen"],["dc.contributor.author","Plinkert, Peter K."],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Rieken, Stefan"],["dc.date.accessioned","2020-07-16T10:32:31Z"],["dc.date.available","2020-07-16T10:32:31Z"],["dc.date.issued","2020"],["dc.description.abstract","The primary aim of our study was to evaluate percutaneous endoscopic gastrostomy (PEG) tube placement depending on body weight and body mass index in patients undergoing radiotherapy (RT) for head and neck cancer (HNC). A secondary aim was to evaluate the course of weight change following PEG placement."],["dc.identifier.doi","10.2147/CMAR.S218432"],["dc.identifier.pmid","32021429"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67165"],["dc.language.iso","en"],["dc.relation.issn","1179-1322"],["dc.title","Percutaneous Endoscopic Gastrostomy Tube Placement in Patients with Head and Neck Cancer Treated with Radiotherapy"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","332.e3"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Clinical Lung Cancer"],["dc.bibliographiccitation.lastpage","340.e3"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Regnery, Sebastian"],["dc.contributor.author","Eichkorn, Tanja"],["dc.contributor.author","Weykamp, Fabian"],["dc.contributor.author","Held, Thomas"],["dc.contributor.author","Weusthof, Katharina"],["dc.contributor.author","Dinges, Lisa-Antonia"],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Winter, Hauke"],["dc.contributor.author","Thomas, Michael"],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Hörner-Rieber, Juliane"],["dc.date.accessioned","2022-11-17T10:17:58Z"],["dc.date.available","2022-11-17T10:17:58Z"],["dc.date.issued","2021"],["dc.description.abstract","Delivery of stereotactic body radiotherapy (SBRT) to ultracentral lung tumors remains a major challenge, with potentially excessive SBRT-related toxicity. This study investigates a risk-optimized approach to ultracentral SBRT in an elderly and comorbid patient cohort."],["dc.identifier.doi","10.1016/j.cllc.2020.11.003"],["dc.identifier.pmid","33281061"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/117098"],["dc.language.iso","en"],["dc.relation.eissn","1938-0690"],["dc.relation.issn","1525-7304"],["dc.title","Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","803"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","International Journal of Radiation Oncology, Biology, Physics"],["dc.bibliographiccitation.lastpage","811"],["dc.bibliographiccitation.volume","105"],["dc.contributor.author","Held, Thomas"],["dc.contributor.author","Windisch, Paul"],["dc.contributor.author","Akbaba, Sati"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","El Shafie, Rami"],["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","Plinkert, Peter"],["dc.contributor.author","Kargus, Steffen"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Herfarth, Klaus"],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Adeberg, Sebastian"],["dc.date.accessioned","2020-07-10T08:22:49Z"],["dc.date.available","2020-07-10T08:22:49Z"],["dc.date.issued","2019"],["dc.description.abstract","This study aimed to assess the feasibility of carbon ion reirradiation (CIR) for recurrent head and neck cancer (HNC)."],["dc.identifier.doi","10.1016/j.ijrobp.2019.07.021"],["dc.identifier.pmid","31349059"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67015"],["dc.language.iso","en"],["dc.relation.eissn","1879-355X"],["dc.relation.issn","0360-3016"],["dc.title","Carbon Ion Reirradiation for Recurrent Head and Neck Cancer: A Single-Institutional Experience"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","294"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Tonndorf-Martini, Eric"],["dc.contributor.author","Schmitt, Daniela"],["dc.contributor.author","Weber, Dorothea"],["dc.contributor.author","Celik, Aylin"],["dc.contributor.author","Dresel, Thorsten"],["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","Hoegen, Philipp"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Paul, Angela"],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Rieken, Stefan"],["dc.date.accessioned","2020-07-16T10:33:44Z"],["dc.date.available","2020-07-16T10:33:44Z"],["dc.date.issued","2019-03-01"],["dc.description.abstract","Pre-operative radiosurgery (SRS) preceding the resection of brain metastases promises to circumvent limitations of post-operative cavity SRS. It minimizes uncertainties regarding delineation and safety margins and could reduce dose exposure of the healthy brain (HB)."],["dc.identifier.doi","10.3390/cancers11030294"],["dc.identifier.pmid","30832257"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67181"],["dc.language.iso","en"],["dc.relation.issn","2072-6694"],["dc.title","Pre-Operative Versus Post-Operative Radiosurgery of Brain Metastases-Volumetric and Dosimetric Impact of Treatment Sequence and Margin Concept"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","568"],["dc.bibliographiccitation.journal","Frontiers in Oncology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Tonndorf-Martini, Eric"],["dc.contributor.author","Schmitt, Daniela"],["dc.contributor.author","Celik, Aylin"],["dc.contributor.author","Weber, Dorothea"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","König, Laila"],["dc.contributor.author","Höne, Simon"],["dc.contributor.author","Forster, Tobias"],["dc.contributor.author","von Nettelbladt, Bastian"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Bernhardt, Denise"],["dc.date.accessioned","2020-07-16T10:33:16Z"],["dc.date.available","2020-07-16T10:33:16Z"],["dc.date.issued","2020"],["dc.description.abstract","Introduction: Stereotactic radiosurgery (SRS) is becoming more frequently used for patients with multiple brain metastases (BMs). Single-isocenter volumetric modulated arc therapy (SI-VMAT) is an emerging alternative to dedicated systems such as CyberKnife (CK). We present a dosimetric comparison between CyberKnife M6 and SI-VMAT, planned at RayStation V8B, for the simultaneous SRS of five or more BM. Patients and Methods: Twenty treatment plans of CK-based single-session SRS to ≥5 brain metastases were replanned using SI-VMAT for delivery at an Elekta VersaHD linear accelerator. Prescription dose was 20 or 18 Gy, conformally enclosing at least 98% of the total planning target volume (PTV), with PTV margin-width adapted to the respective SRS technique. Comparatively analyzed quality metrics included dose distribution to the healthy brain (HB), including different isodose volumes, conformity, and gradient indices. Estimated treatment time was also compared. Results: Median HB isodose volumes for 3, 5, 8, 10, and 12 Gy were consistently smaller for CK-SRS compared to SI-VMAT (p < 0.001). Dose falloff outside the target volume, as expressed by the gradient indices GI_high and GI_low, was consistently steeper for CK-SRS compared to SI-VMAT (p < 0.001). CK-SRS achieved a median GI_high of 3.1 [interquartile range (IQR), 2.9-1.3] vs. 5.0 (IQR 4.3-5.5) for SI-VMAT (p < 0.001). For GI_low, the results were 3.0 (IQR, 2.9-3.1) for CK-SRS vs. 5.6 (IQR, 4.3-5.5) for SI-VMAT (p < 0.001). The median conformity index (CI) was 1.2 (IQR, 1.1-1.2) for CK-SRS vs. 1.5 (IQR, 1.4-1.7) for SI-VMAT (p < 0.001). Estimated treatment time was shorter for SI-VMAT, yielding a median of 13.7 min (IQR, 13.5-14.0) compared to 130 min (IQR, 114.5-154.5) for CK-SRS (p < 0.001). Conclusion: SI-VMAT offers enhanced treatment efficiency in cases with multiple BM, as compared to CyberKnife, but requires compromise regarding conformity and integral dose to the healthy brain. Additionally, delivery at a conventional linear accelerator (linac) may require a larger PTV margin to account for delivery and setup errors. Further evaluations are warranted to determine whether the detected dosimetric differences are clinically relevant. SI-VMAT could be a reasonable alternative to a dedicated radiosurgery system for selected patients with multiple BM."],["dc.identifier.doi","10.3389/fonc.2020.00568"],["dc.identifier.pmid","32457829"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67175"],["dc.language.iso","en"],["dc.relation.issn","2234-943X"],["dc.title","Single-Isocenter Volumetric Modulated Arc Therapy vs. CyberKnife M6 for the Stereotactic Radiosurgery of Multiple Brain Metastases"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","340"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Clinical Lung Cancer"],["dc.bibliographiccitation.lastpage","345"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","König, Laila"],["dc.contributor.author","Aufderstrasse, Sophie"],["dc.contributor.author","Krisam, Johannes"],["dc.contributor.author","Hoerner-Rieber, Juliane"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Bozorgmehr, Farastuk"],["dc.contributor.author","El Shafie, Rami"],["dc.contributor.author","Lang, Kristin"],["dc.contributor.author","Kappes, Jutta"],["dc.contributor.author","Thomas, Michael"],["dc.contributor.author","Herth, Felix"],["dc.contributor.author","Heußel, Claus Peter"],["dc.contributor.author","Warth, Arne"],["dc.contributor.author","Marcrom, Samuel"],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Steins, Martin"],["dc.contributor.author","Rieken, Stefan"],["dc.date.accessioned","2020-07-10T08:21:58Z"],["dc.date.available","2020-07-10T08:21:58Z"],["dc.date.issued","2018"],["dc.description.abstract","Patients with small-cell lung cancer (SCLC) demonstrate an exception in the treatment of brain metastases (BM), because in patients with SCLC whole brain radiotherapy (WBRT) only is the preferred treatment modality. The purpose of this study was to develop a prognostic score for patients with brain metastases from SCLC treated with WBRT."],["dc.identifier.doi","10.1016/j.cllc.2017.12.004"],["dc.identifier.pmid","29373273"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67004"],["dc.language.iso","en"],["dc.relation.eissn","1938-0690"],["dc.relation.issn","1525-7304"],["dc.title","Generation of a New Disease-specific Prognostic Score for Patients With Brain Metastases From Small-cell Lung Cancer Treated With Whole Brain Radiotherapy (BMS-Score) and Validation of Two Other Indices"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","jnumed.120.245084"],["dc.bibliographiccitation.journal","Journal of Nuclear Medicine"],["dc.contributor.author","Giesel, Frederik"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Syed, Mustafa"],["dc.contributor.author","Lindner, Thomas"],["dc.contributor.author","Jimenez, Luis David"],["dc.contributor.author","Mavriopoulou, Eleni"],["dc.contributor.author","Staudinger, Fabian"],["dc.contributor.author","Tonndorf-Martini, Eric"],["dc.contributor.author","Regnery, Sebastian"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","El Shafie, Rami"],["dc.contributor.author","Röhrich, Manuel"],["dc.contributor.author","Flechsig, Paul"],["dc.contributor.author","Kluge, Andreas"],["dc.contributor.author","Altmann, Annette"],["dc.contributor.author","Debus, Juergen"],["dc.contributor.author","Haberkorn, Uwe A."],["dc.contributor.author","Kratochwil, Clemens"],["dc.date.accessioned","2020-07-16T10:32:35Z"],["dc.date.available","2020-07-16T10:32:35Z"],["dc.date.issued","2020-06-26"],["dc.description.abstract","68Ga-FAPI-2/4/46 have already been proposed as promising PET-tracers. However, the short half-life of 68Ga (T1/2 68 min) creates problems with manufacture and delivery. 18F (T1/2 110 min) labeling would result in a more practical large scale production and a cold-kit formulation would improve the spontaneous availability. The NOTA-chelator ligand FAPI-74 can be labeled with both 18F-AlF (Aluminum-Fluoride) and 68Ga. Here we describe the in-vivo evaluation of 18F-FAPI-74 and a proof-of-mechanism of 68Ga-FAPI-74 labeled at ambient temperature. Methods: In ten patients with lung cancer PET-scans were acquired at 10 min, 1h and 3H after administration of 259±26 MBq 18F-FAPI-74. Physiological biodistribution and tumor uptake were semi-quantitatively evaluated based on SUV at each time-point. Absorbed doses were evaluated using OLINDA/EXM 1.1 and QDOSE dosimetry software with the dose calculator IDAC-Dose 2.1. Identical methods were used to evaluate one exam after injection of 263 MBq 68Ga-FAPI-74. Results: The highest contrast was achieved 1 h p.i. in primary tumors, lymph node and distant metastases with SUVmax >10, respectively. The effective dose per 100 MBq administered activity of 18F-FAPI-74 was 1.4±0.2 mSv and for 68Ga-FAPI-74 it was 1.6 mSv. Thus, the radiation burden of a diagnostic 18F-FAPI-74 PET-scan is even lower than that of PET-scans with 18F-FDG and other 18F-tracers; 68Ga-FAPI-74 is comparable to other 68Ga-ligands. FAPI-PET/CT supported target volume definition for guiding radiotherapy. Conclusion: High contrast and low radiation burden of FAPI-74 PET/CT favors multiple clinical applications. Centralized large-scale production of 18F-FAPI-74 or decentralized cold-kit labeling of 68Ga-FAPI-74 allows flexible routine use."],["dc.identifier.doi","10.2967/jnumed.120.245084"],["dc.identifier.pmid","32591493"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67166"],["dc.language.iso","en"],["dc.relation.eissn","1535-5667"],["dc.relation.issn","0161-5505"],["dc.relation.issn","2159-662X"],["dc.title","FAPI-74 PET/CT Using Either 18F-AlF or Cold-kit 68Ga-labeling: Biodistribution, Radiation Dosimetry and Tumor Delineation in Lung Cancer Patients"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]